A study of 608 for non-radiographic axial spondyloarthritis
Part of Bones, joints & muscles clinical trials.
This study tests a new medicine called 608 for people with non-radiographic axial spondyloarthritis (a type of inflammatory back pain). The goal is to see if it can reduce pain and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-radiographic axial spondyloarthritis (a type of inflammatory arthritis that doesn't show on X-rays).
- You have signs of inflammation in your spine or joints, seen on MRI or in a blood test (like elevated C-reactive protein).
- Your back pain is at least 4 out of 10 on a pain scale at the start of the study.
- You do not have active hepatitis B, C, HIV, or a history of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pain-relieving drug called acemetacin for people with axial spondyloarthritis (a type of arthritis affecting the spine and pelvis). The drug aims to reduce pain and inflammation, and this study will see how well it works in real life.
This trial looks at people with low back pain to find early signs of a spine arthritis condition. It may help diagnose the condition sooner and guide better treatment.
This trial tests whether taking nonsteroidal anti-inflammatory drugs (NSAIDs) helps people with axial spondyloarthritis stay in remission and avoid future flare-ups. It’s meant to see if NSAIDs can reduce the chance of symptoms returning and keep disease activity low over time.
This trial tests a new medication called vilamakitug to see if it can reduce pain and inflammation in people with axial spondyloarthritis, a type of arthritis that affects the spine and joints. It may help those who haven't found relief with other treatments.
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
This study tests a new medication (called 608) to see if it helps reduce pain and inflammation in people with a type of spinal arthritis that isn't visible on X-rays. If you have persistent back pain and signs of inflammation, this treatment might offer a new option to feel better.
Hear when a new Axial Spondyloarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.